| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
NAGKi targets N-acetylglucosamine kinase (NAGK) and N-acetylmannosamine kinase (NAMK). It acts as a competitive inhibitor of NAGK with a Ki of 17 µM and a non-competitive inhibitor of NAMK with a Ki of 80 µM in rat liver in vitro. NAGK catalyzes the phosphorylation of N-acetylglucosamine to N-acetylglucosamine-6-phosphate, a key step in hexosamine metabolism. The compound does not inhibit glucokinase, demonstrating selectivity for NAGK over other hexokinases.
|
|---|---|
| ln Vitro |
NAGKi potently inhibits glucose phosphorylation by N-acetylglucosamine kinase with a Ki of 17 µM, while glucokinase is not affected. It also inhibits N-acetylmannosamine kinase with a Ki of 80 µM. These inhibitory activities have been characterized in rat liver in vitro. The compound's selectivity for NAGK over glucokinase makes it a useful tool for dissecting the specific roles of these enzymes in metabolic pathways.
|
| ln Vivo |
No specific in vivo activity data have been published for NAGKi. As a research tool for studying hexosamine metabolism, its effects on systemic metabolism, protein glycosylation, or disease progression have not been extensively characterized in animal models. The compound's utility is currently confined to in vitro biochemical and cell-based assays of NAGK and NAMK function.
|
| Enzyme Assay |
For non-cell enzyme inhibition assays, recombinant NAGK or NAMK is incubated with the substrate (N-acetylglucosamine or N-acetylmannosamine) and ATP in the presence of NAGKi at various concentrations. Kinase activity is measured by detecting ADP production using a coupled enzymatic assay or by HPLC quantification of the phosphorylated product. Ki values are calculated from dose-response curves.
|
| Cell Assay |
For cell-based assays, cells are cultured in standard media and treated with NAGKi at various concentrations. Intracellular levels of N-acetylglucosamine-6-phosphate and other hexosamine metabolites are measured by mass spectrometry or HPLC. Effects on protein glycosylation can be assessed by lectin blotting or mass spectrometry. Cell viability is monitored by MTT assay.
|
| Animal Protocol |
No specific in vivo animal protocol has been published for NAGKi. If in vivo evaluation is desired, a general approach would involve administering the compound to rodents by intraperitoneal or oral routes at doses extrapolated from in vitro effective concentrations, followed by analysis of tissue hexosamine metabolites by mass spectrometry. However, no validated in vivo protocols exist in the literature.
|
| References |
| Molecular Formula |
C9H17NO6
|
|---|---|
| Molecular Weight |
235.24
|
| Exact Mass |
235.106
|
| CAS # |
94825-74-8
|
| PubChem CID |
53230018
|
| Appearance |
White to off-white solid powder
|
| Density |
1.368g/cm3
|
| Boiling Point |
542.355ºC at 760 mmHg
|
| Melting Point |
189-191ºC
|
| Flash Point |
281.806ºC
|
| Index of Refraction |
1.534
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
248
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[C@H](OC)([C@H](O)[C@H](O)CO)[C@H](C=O)NC(=O)C
|
| InChi Key |
SXGSBXSSPNINRW-VARJHODCSA-N
|
| InChi Code |
InChI=1S/C9H17NO6/c1-4(12)10-6-8(15-2)7(13)5(3-11)16-9(6)14/h5-9,11,13-14H,3H2,1-2H3,(H,10,12)/t5-,6-,7-,8-,9?/m1/s1
|
| Chemical Name |
N-[(3R,4R,5S,6R)-2,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-3-yl]acetamide
|
| Synonyms |
NAGK-i; NAGKi; 3-O-Methyl-N-acetyl-D-glucosamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~30 mg/mL (~127.5 mM; with ultrasonication and warming)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2510 mL | 21.2549 mL | 42.5098 mL | |
| 5 mM | 0.8502 mL | 4.2510 mL | 8.5020 mL | |
| 10 mM | 0.4251 mL | 2.1255 mL | 4.2510 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
